A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for Moderna as it seeks to expand its commercial pipeline beyond COVID-19.
Arbutus Biopharma Corporation (NASDAQ:ABUS): Settlement Windfall Drives Net Profitability
It was reported on July 16 that Arbutus Biopharma Corporation scored a decisive victory after receiving approximately $178 million from Moderna, Inc., its share of the $950 million noncontingent settlement payment made through its licensee, Genevant Sciences. The payment includes reimbursement of legal costs, and Arbutus expects an additional dividend in Q3 from its ~16% equity stake in Genevant’s parent. Following this influx, Arbutus announced plans to return $230 million in capital to shareholders.
Separately, regarding the corporation’s Q1 2026 financials, total revenue surged to $179.1 million from $1.8 million in Q1 2025, driven by $178.7 million in settlement-related license revenue. Driven by cost-cutting initiatives and workforce reductions, operating expenses declined to $10.2 million (with R&D expenses cut to $4.1 million), delivering a net income of $169.7 million ($0.88 per share) versus a net loss of $24.5 million a year earlier. ABUS ended Q1 2026 with $95.2 million in cash, cash equivalents, and marketable securities, providing a lean, stable foundation alongside Fast Track designation for its lead hepatitis B candidate, imdusiran.
Moderna, Inc. (NASDAQ:MRNA): Expanding Pipeline Amid Revenue Normalization
Moderna, Inc. continues to transition from peak COVID-19 vaccine sales into a broader mRNA therapeutics power. On August 6, a major commercial milestone arrived as Moderna secured FDA approval for mFLUSIVA, its seasonal influenza vaccine for adults 50 years and older, marking the company’s fifth approved product. Moderna also advanced late-stage programs in oncology (intismeran with Merck) and RSV (mRESVIA), maintaining a target of up to 10% overall revenue growth for 2026.
Moderna’s Q2 2026 earnings highlight the high costs of commercial scaling and R&D. Second-quarter total revenue was $145 million, up slightly from $142 million in Q2 2025. Total operating expenses stood at $960 million, including $651 million in R&D and $216 million in SG&A, yielding a net loss of $782 million ($1.97 per share). MRNA closed Q2 2026 with $6.9 billion in cash, cash equivalents, and investments before remitting the $950 million settlement payment in July 2026. The company lowered its full-year 2026 operating expense outlook by $0.2 billion and projects year-end cash between $4.7 billion and $5.2 billion.
Financial Projections and Strategic Catalysts
Comparing financial performance across Arbutus’ Q1 2026 and Moderna’s Q2 2026 shows two distinct profiles. Arbutus temporarily stands out in bottom-line profitability and capital efficiency, generating $169.7 million in quarterly net income on $10.2 million in operating expenses, allowing a substantial shareholder payout. Moderna operates at a far larger scale: despite quarterly net losses of $782 million and heavy cash burn, its $6.9 billion balance sheet funds an expansive late-stage clinical pipeline that micro-cap biotechs cannot match.
The bull case for ABUS centers on its $230 million capital return plan, reduced burn rate, and potential upside from a $1.3 billion contingent payout pending an appellate ruling on federal patent claims. The bear case notes that Arbutus’ profitability is non-recurring, relying on legacy IP litigation rather than sustained commercial product revenues, while its clinical pipeline remains concentrated.
The bull case for MRNA relies on its commercial infrastructure and mRNA platform versatility, with mFLUSIVA joining its commercial lineup alongside promising Phase 3 readouts in oncology and rare diseases. The bear case highlights ongoing operating losses, pipeline setbacks (such as its norovirus candidate missing early interim efficacy criteria), and diminished post-pandemic COVID-19 revenues.
Insider Monkey’s Hedge Fund Data
Insider Monkey’s hedge fund database shows shifting institutional interest across both tickers.
For Arbutus Biopharma Corporation (NASDAQ:ABUS), hedge fund holdings slightly decreased to 25 funds in Q1 2026 from 27 in Q4 2025. Two Seas Capital, managed by Sina Toussi, held the largest position with 18,557,543 shares valued at $83.51 million (+48% activity, representing 1.17% of portfolio). Whitefort Capital, managed by David Salanic, held 14,930,885 shares valued at $67.19 million (+12% activity, making up a significant 19.81% of the portfolio).
For Moderna, Inc. (NASDAQ:MRNA), institutional participation expanded to 52 hedge funds in Q1 2026 from 48 in Q4 2025. Among notable institutional moves, Walleye Capital, managed by Will England, held 134,800 CALL shares valued at $9.44 million (-56% activity) alongside 113,700 PUT shares valued at $7.96 million (-30% activity), reflecting hedged positioning around Moderna’s regulatory and pipeline catalysts.
Conclusion
While Moderna, Inc. (NASDAQ:MRNA) holds the long-term commercial scale and capital to advance multi-billion-dollar mRNA therapies, Arbutus Biopharma Corporation (NASDAQ:ABUS) achieved the clearer short-term financial victory. By monetizing its patent portfolio into a $178 million payout and returning $230 million to shareholders, Arbutus proved that IP defense can deliver immediate value even during clinical development.
While we acknowledge the risk and potential of ABUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABUS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
